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outputs include total costs (Singapore dollars (SGD); 1 SGD=0.82 USD), IFIs 
avoided, life-years saved, and incremental cost-effectiveness of posaconazole 
versus fluconazole/ itraconazole. A probabilistic sensitivity analysis (PSA) was 
conducted, where probabilities of IFI, IFI-related death, and 100-day other cause 
mortality were assigned beta distributions from trial data. RESULTS: Total costs 
of prophylaxis with fluconazole/ itraconazole and posaconazole were SGD 4,475 
and SGD 4,999, respectively. Corresponding health outcomes were 0.11 and 0.05 
IFIs and 2.44 and 2.51 life-years. Incremental cost-effectiveness ratios for 
posaconazole were SGD 8,150 per IFI avoided and SGD 7,526 per life-year saved. 
Posaconazole was cost-effective compared to fluconazole/ itraconazole in 94% of 
PSA simulations at a threshold of SGD 80,000 (commonly cited threshold in 
Singapore). CONCLUSIONS: Use of posaconazole in place of fluconazole/ 
itraconazole for prevention of IFIs in a high-risk neutropenic population is cost-
effective at a willingness-to-pay threshold of SGD 80,000 per life-year saved in 
Singapore.  
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OBJECTIVES: To examine the overall incremental cost and survival benefit 
associated with the receipt of second line chemotherapy/biologics (Tx2) among 
elderly Medicare metastatic colon cancer (mCC) patients who had received first 
line chemotherapy/biologics treatment (Tx1). METHODS: Elderly (66+) SEER-
Medicare patients diagnosed with mCC in 2003-2007 were identified and 
followed until death or 12/31/09. The analysis was restricted to patients who 
received any chemotherapy/biologics treatment. Cox regression and partitioned 
least squares regression were utilized to obtain the incremental survival benefit 
and the overall incremental cost associated with the receipt of Tx2 within a five-
year period, respectively. The regressions controlled for patient demographic 
and clinical characteristics including cancer related measures, Charlson 
comorbidity index and proxy for poor performance status. Bootstrapping was 
used to produce 95% confidence intervals (CI). RESULTS: Of the 3,266 elderly 
Medicare mCC who received Tx1, 2,744 (84%) died within the observation period; 
1,440 (44%) received Tx2; 274(8%) received subsequent treatments. The 
incremental survival benefit associated with the receipt of Tx2 was 0.631 years 
(CI: 0.517 − 0.761), and the associated overall incremental cost was $107,027 (CI: 
93,401 − 120,887). The incremental cost-effectiveness ratio for Tx2 was $169,722 
per life year gained (CI: 137,139 − 208,134). CONCLUSIONS: The estimated 
survival benefit of receiving second line chemotherapy/biologics treatment 
ranges from 6 to 9 months, which is consistent with evidence from clinical trials. 
This improved survival was associated with costs that are slightly above 
$100,000.  
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BACKGROUND: Metastatic melanoma (MM) is the deadliest form of skin cancer. 
It’s associated with high mortality with a median overall survival (OS) of 6 to 9 
months. Ipilimumab is the first agent to improve the survival of metastatic 
melanoma patients and to provide long-term benefit to a proportion of patients 
treated within phase II/III studies and expanded access programs. OBJECTIVES: 
To evaluate the cost-effectiveness of ipilimumab in previously treated patients 
for advanced melanoma compared to Best Supportive Care (BSC) from a 
Portuguese national payer perspective. METHODS: A three-state Markov model 
with stable disease, progression and death was developed. The model assumed 
three-week cycles, and the analysis assumed a lifetime time horizon. Costs and 
consequences were discounted at 5%. Patient-level data from the pivotal Phase 
III MDX010-20 trial was used to describe the survival of ipilimumab 3mg/kg and 
BSC (based on the gp100 arm of the trial). Extrapolation methods were used to 
model long-term survival beyond the trial. Clinical practice and resource 
utilization were assessed from a survey of Portuguese oncologists and 
dermatologists. Unit costs were obtained from official sources and outcomes 
were described in life years (LY) gained. One-way and probabilistic SA were also 
undertaken. RESULTS: Ipilimumab was associated with an additional gain of 1.29 
LY when compared to BSC, with an incremental cost-effectiveness ratio of 
€53,579/LY. Results were most sensitive to different survival extrapolation 
assumptions and the treatment cost. Probabilistic SA showed a >95% likelihood 
that ipilimumab is cost-effective at a willingness to pay threshold of €59,000/LY. 
CONCLUSIONS: Ipilimumab offers a significant survival benefit when compared 
with BSC, but at a higher cost. Given the high unmet need, small number of 
advanced melanoma patients and robust sensitivity analyses; it is likely that 
ipilimumab represents a cost-effective treatment for previously treated 
advanced melanoma patients in Portugal.  
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OBJECTIVES: Dosing of chemotherapy regimens using 5-fluorouracil (5-FU) in 
patients with metastatic colorectal cancer (mCRC) is based on body surface area 
(BSA), which has been shown to yield suboptimal plasma 5-FU levels. 
Pharmacokinetic (PK) monitoring of 5-FU shows promise in terms of optimal 
dosing, but its cost-effectiveness is unknown. This study performs a cost-
effectiveness analysis of PK dosing versus BSA dosing of 5-FU among patients 
with mCRC in the UK. METHODS: A decision tree model was used to perform a 
counterfactual simulation of the cost-effectiveness of PK versus BSA dosing of 5-
FU in standard chemotherapy regimens for mCRC in the UK population. All 
patients were assumed to receive first-line therapy for 6 or 12 cycles or until 
progression, after which they received standard post-first-line chemotherapy 
and subsequent palliative care until death. Costs were estimated from the 
perspective of the national health system as payer, were drawn from the 
literature and publically available national unit cost estimates. Effectiveness was 
quality adjusted life years (QALY), with utilities estimated from the literature. 
Discounting was performed at 3% per year. Incremental cost-effectiveness ratios 
comparing PK to BSA dosing were computed for the six most common 
chemotherapy regimens that utilize 5-FU. RESULTS: The average ICER across all 
regimens and weighted by their current distribution was £7,336 per incremental 
QALY gained. The ICER for lifetime discounted incremental cost per incremental 
QALY for PK versus BSA dosing was £3,467 for a FOLFOX4 regimen, £3,594 for a 
FOLFOX6 regimen, £23,428 for FOLFIRI, £3,508 for FOLFOX6 + bevacizumab, 
£21,874 for FOLFIRI + bevacizumab, and £28,862 for a 5-FU + leucovorin 
chemotherapy regimen. CONCLUSIONS: PK dose management of 5-FU based 
chemotherapy regimens for patients with mCRC appears cost-effective from a 
UK national payer perspective. Cost-effectiveness was driven in part by better 
efficacy and reduced adverse events.  
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OBJECTIVES: Metastatic renal cell carcinoma (mRCC) is one of the most common 
adult malignancies. Overall survival (OS) without treatment ranges from 6 to 12 
months and in Ecuador, 269 patients were estimated in 2008 with mRCC. The 
aim of this study was to assess the cost-effectiveness of first-line therapies for 
patients with mRCC from the payer’s perspective over five years. METHODS: 
Cost–effectiveness and cost-utility analyses were developed using a Markov 
model to compare within a six-week cycle: sunitinib (50mg/day, four weeks 
treatment and two week off) versus sorafenib (800mg/day) and bevacizumab 
(10mg/kg bi-weekly) + IFN (9MU every 3 weeks). Model contains 5 health states 
(first-line treatment-no progression-, second-line treatment, palliative care, 
death due to mRCC and death due to other causes). It simulates overall costs, 
progression free-years (PFY), life years gained (LYG) and Quality Adjusted Life 
Years (QALYs) gained. Transition probabilities/utilities were obtained from 
previous published trials. Resource use and costs data was obtained from 
National Ecuadorian Health Formulary (Minister of Health 2012) which includes 
costs data from MoH Centers, IESS, Military Hospital and Police Hospital). Official 
Epi data from the Ecuadorian Institute of Social Security (IESS), Globocan, SOLCA, 
and other local institutions were considered. Both costs and effectiveness were 
discounted using a 5% annual rate. RESULTS: First-line treatment with sunitinib 
showed the highest PFY, LYG and QALYs (1.27; 2.35; 1.56 years, respectively) 
followed by bevacizumab+IFN- (1.11; 2.22; 1.45 years) and sorafenib (0.81; 2.26; 
1.43 years). Expected health care costs related to sunitinib resulted lower: 
US$72,599 versus US$111,286 for sorafenib and US$ 192,208 for 
bevacizumab+IFN. Other costs related with therapy administration, caregivers 
and adverse events were also lower with sunitinib. Probabilistic sensitivity 
analyses showed robustness of these results CONCLUSIONS: Sunitinib is cost–
saving among the new agents for patients with mRCC, achieving higher clinical 
outcomes and lower costs in Ecuador.  
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OBJECTIVES: Prevention of the painful, debilitating and costly skeletal 
complications of BM is an important therapy goal. We aimed to evaluate the 
cost-effectiveness of denosumab (120mg Q4W) versus ZA (4 mg Q4W) in the 
prevention of SRE in prostate cancer patients with BM from the public health 
care setting in Mexico. METHODS: A three-state (on/off treatment and dead) 
lifetime Markov model with 4-week cycles was developed in order to estimate 
the incremental cost-effectiveness ratio (ICER) per SRE avoided. The real-world 
SRE rates in ZA-treated patients were derived from a large commercial database 
and used together with the trial-based treatment effect for denosumab versus 
ZA to estimate the denosumab SRE rate. ZA acquisition cost was gathered from 
local public tenders. Unit cost for medical consultation, drug´s administration 
and laboratory tests were obtained from official lists. Diagnosis-related group 
data were used to assess the costs attributable to SRE. Costs are expressed in 
2012 Mexican pesos. Overall survival was similar between the treatment arms of 
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the clinical trial and assumed equal in the models. Costs and outcomes beyond 
first year were discounted at a 5% annual rate. RESULTS: Denosumab was 
associated with lower frequency of SRE due to clinical superiority versus ZA, and 
with higher costs. The incremental cost per SRE avoided was estimated at 
$78,844. Although a formal threshold for this outcome is not available in Mexico, 
the ICER obtained is 40% below the commonly accepted threshold in Mexico 
(based on the GDP per capita). The ICER remained below the local accepted 
threshold in all univariate sensitivity analyses. In the probabilistic sensitivity 
analysis, denosumab became the most preferred option from a willingness to 
pay of approximately 100 000 Mexican pesos. CONCLUSIONS: These results 
suggest denosumab represents good value for money in the prevention of SRE in 
prostate cancer patients with BM in Mexico.  
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OBJECTIVES: To evaluate the most cost-effective strategy of staging non-small 
cell lung cancer with hybrid PET/CT to avoid unnecessary surgeries. METHODS: 
A decision tree model was developed with four work-up approaches: CT alone, 
PET/CT for all, PET/CT when negative CT, and CT plus PET/CT for all. 
Mediastinoscopy was included in all alternatives to confirm positive CT or 
PET/CT. Surgery was considered unnecessary when the work-up drives to 
resectable stage but the model predicts loco regional or distant metastasis. The 
model incorporated evidence-based data from the literature and associated costs 
were evaluated from the Brazilian public health care system perspective. The 
costs of PET/CT in Brazil were estimated in previous study by microcosts 
technique. The impact of uncertainties on the model was verified by 
deterministic and probabilistic sensitivity analyses (PSA). RESULTS: For each 
strategy, a simulation of 1000 individuals has shown the costs and effects (US$/ 
avoidable surgery) as follow: US$1.088.248,85/ 0; US$2.620.087,94/ 151; 
US$2.432.104,45/ 170 and US$2.740.718,99/ 181, respectively. The incremental 
cost-effectiveness ratio (ICER) per avoidable surgery was more favorable for 
PET/CT in negative CT (US$7.888/ surgery) than PET/CT for all (US$10.127/ 
surgery) and CT plus PET/CT (US$9.108/ surgery) versusCT alone. In sensitivity 
analysis, estimates of ICER were sensitive to changes in the probability of distant 
metastasis, the cost of PET/CT procedure and probability of N0/1 disease. 
CONCLUSIONS: Although PET/CT is recommended for staging potential 
resectable lung cancer patients, the procedure is not reimbursed in Brazilian 
public health care system yet. Our study shows that include PET/CT in the work-
up staging of lung cancer could prevent misleading surgeries due to undiagnosed 
advanced disease. In term of cost-effectiveness, PET/CT in negative CT patients 
is the most cost-effective strategy with a probability higher than 90% when the 
willingness-to-pay is US$10.000,00 superior.  
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OBJECTIVES: To evaluate the cost-effectiveness of using Oncotype DXTM to 
inform adjuvant chemotherapy treatment decisions versus standard clinical 
practice (use of traditional clinical and pathological criteria). Oncotype DX is a 
21-gene assay that provides an individualized prediction of chemotherapy 
benefit and 10-year distant recurrence for patients with hormone receptor 
positive, human epidermal growth receptor 2 negative (HER2–), early-stage 
breast cancer. METHODS: A Markov model was developed to make long-term 
projections of distant recurrence, survival, and direct costs for patients described 
above. Scenarios using Oncotype DX to inform treatment recommendations for 
adjuvant chemotherapy or conventional procedures were modeled based on 
published decision impact studies. Transition probabilities and risk adjustment 
were based on published landmark trials. Costs are reported in U.S. dollars at an 
exchange rate of 13.17 MXN per dollar (average 2012) and were estimated from 
an Instituto Mexicano del Seguro Social (IMSS) perspective based on published data. 
Future costs and clinical benefits were discounted at 5% annually. Sensitivity 
analyses were performed. RESULTS: 29.5% of early-stage breast cancer patients 
were spared chemotherapy following Oncotype DX testing, whilst 5.6% of 
patients received chemotherapy in addition to hormone therapy. Long-term 
modeling analysis showed that optimized therapy allocation following Oncotype 
DX testing led to an improvement in mean life-expectancy of 0.068 years per 
patient and increased direct costs by $129.6 per patient versus usual care. This 
equated to an incremental cost effectiveness ratio (ICER) of $1,917 per life-year 
gained. In a secondary analysis of patients previously recommended 
chemotherapy, use of Oncotype DX was associated with avoidance of 
chemotherapy in 46% of patients, leading to cost savings of $2,082 per patient, 
with life expectancy maintained at the level expected with standard care. 
CONCLUSIONS: Using Oncotype DX was projected to be cost-effective in 
comparison with the current standard of care.  
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OBJECTIVES: To evaluate the cost-effectiveness of primary and secondary 
prophylaxis (PP and SP) with pegfilgrastim, filgrastim (6-day and 11-day), or no 
prophylaxis for decreasing the incidence of febrile neutropenia (FN) in recurrent 
ovarian cancer patients receiving 3 cycles of myelosuppressive chemotherapy 
(docetaxel every 21 days 100 mg/m2, FN risk ≥20%) over a lifetime horizon from a 
U.S. payer perspective. METHODS: A Markov cycle tree model tracks FN events in 
chemotherapy cycles 1-3 (3-week cycles) and long-term survival (1-year cycles). 
Long-term survival is modeled according to received relative dose intensity (RDI), 
which correlates with FN history. Model inputs, including efficacy (relative risk of 
FN compared to no prophylaxis) of each strategy, effects of FN on RDI, mortality, 
costs, and utilities, were estimated from public sources, research databases, and 
peer-reviewed publications. Expected lifetime costs and quality-adjusted life-
years (QALYs) (discounted 3% per year) were estimated for each strategy. 
Probabilistic sensitivity analyses (PSA) were conducted. RESULTS: The 
incremental cost-effectiveness ratio (ICER) for PP versus SP with pegfilgrastim 
was $15,946 per QALY gained. Total lifetime costs for PP and SP with 
pegfilgrastim were $13,034 and $12,704, respectively, while lifetime QALYs were 
0.916 and 0.895. PP with pegfilgrastim dominated all other comparators. 
Although ICER results of PP versus SP with pegfilgrastim may be affected by 
changes in baseline FN risk, pegfilgrastim efficacy, pegfilgrastim cost, and cost of 
FN-related hospitalization, PP was cost-effective compared to SP in 95% and 
100% of PSA simulations at thresholds of $50,000 and $100,000 per QALY, 
respectively. CONCLUSIONS: From a U.S. payer perspective, PP with 
pegfilgrastim is cost-effective compared to other prophylaxis strategies in 
recurrent ovarian cancer patients receiving docetaxel.  
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OBJECTIVES: Prostate cancer is the most common malignancy in the male. It has 
become a major public health problem in the Bahamas particularly among blacks 
and identified as one of the major contributors to mortality. Luteinizing hormone 
releasing hormone (LHRH) agonist monotherapy is the first line treatment in 
cases of metastatic prostate cancer as Bahamian patients generally refuse 
surgical castration. Among the available LHRH agonist, goserelin and luprolide 
are the only two drugs that are available on the Bahamas national drug 
formulary. The objective of this study was to conduct a cost effectiveness 
analysis of goserelin acetate 10.8 mg depot versus leuprolide acetate 7.5 mg 
depot in the treatment of metastatic prostate cancer in the Bahamas, from a 
societal perspective. METHODS: Cost and probabilities of outcomes were derived 
from the hospital data and published literature. Direct & indirect costs included 
were physician and nursing cost, drug cost, diagnostic and lab costs; loss of 
wages and cost of travel. Primary outcomes were month of life gained and 
adverse events. A one way sensitivity analyses were conducted by varying the 
cost and survival by 25%. Hospital data on survival was reviewed for 2 years from 
the initiation of treatment. RESULTS: The cost effectiveness analysis showed 
that the leuprolide was the least costly alternative to goserelin (US$6268 vs. 
$7156 per patient). The incremental cost effectiveness ratio (ICER) of leuprolide 
compared to goserelin was $286 per month of life gained. Results were sensitive 
to variations in costs and month of life gained by 25% proving leuprolide being a 
dominant option over goserelin. Leuprolide was found being less expensive both 
to the patient as well as to the payer. CONCLUSIONS: Lueprolide appears to be 
the least costly approach for the treatment of metastatic prostate cancer in the 
Bahamas, from a societal perspective. Further investigations are needed to 
confirm its cost effectiveness considering other cost variables & quality of life.  
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OBJECTIVES: Tamoxifen and raloxifene has been approved by US FDA for breast 
cancer chemoprevention. Exemestane was also found to have promising effects 
on breast cancer prevention based on 3 years follow-up of MAP.3 trial. The 
objective of the study was to assess the cost-effectiveness of continuing therapy 
with tamoxifen for 5 years versus switching to exemestane or raloxifene, after 2 
years of treatment with tamoxifen in postmenopausal women in the United 
States from third party payer perspective. METHODS: A Markov model was 
developed using Treeage pro suite 2009, where cost and health outcomes were 
utilized for estimating quality adjusted life year (QALY). A hypothetical cohort of 
1000 women with 5 year predicted breast cancer risk (≥ 1.66) based on the Gail et 
al. model, history of lobular carcinoma in-situ, and history of atypical 
hyperplasia was simulated using the Markov model. The model was developed 
comprising of 5 health states (Healthy, Adverse Event, Breast Cancer, Death  
due to Breast Cancer, and Death due to Other Causes) to calculate incremental 
costs per QALY gains for tamoxifen, raloxifene and exemestane. Annual 
transition probabilities were derived from NSABP P-1 and NSABP P-2 trials (for 
tamoxifen and raloxifene) and MAP.3 trial (for exemestane). Direct costs and 
utilities were literature-based. Costs and benefits were discounted at 3% 
